TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03996941

Intervention type: BEHAVIORAL
Intervention: Harm reduction of informal PrEP use
Description: Users attending the study center interested in PrEP use , as well as those who could benefit from it are invited to attend an information session in which issues are touched like the effectiveness and safety of PrEP, and the characteristics of the SeguiPrEP program. This program consists of periodic clinical controls (five during the first year and four in the following period) that include: physical examination, HIV and other STI screening, control of renal functions, estimation and promotion of PrEP adherence, monitoring of adverse events associated with PrEP and counseling.~Those who decide to use PrEP or who are already using PrEP are asked to schedule an initiation visit.

Intervention type: OTHER
Intervention: PrEP follow up based on point of care testing
Description: The study center has a point-of-care technology based laboratory, which allows obtaining immediate results in order to reduce the loss of follow-up.
Study: NCT05973318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzotimol eye drops, 20 mg/mL + 5 mg/mL
Description: Dosing schedule b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosopt eye drops, 20 mg/mL + 5 mg/mL
Description: Dosing schedule b.i.d.
Study: NCT02235363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thread lift
Description: In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
Study: NCT03169634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: short or long stemmed rTKR cemented
Description: An evaluation of the outcomes of different ways of performing revision total knee replacement surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone with short stem
Description: Revision knee replacement using a metaphyseal cone and then a knee replacement with short stems is cemented in to it

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone with long stem
Description: Revision knee replacement using a metaphyseal cone and then a knee replacement with long stems is cemented in to it
Study: NCT04325087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: Administration of an iTBS protocol over the dlPFC

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo iTBS
Description: Administration of a placebo TMS protocol over the dlPFC
Study: NCT00612157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Description: Eszopiclone 3mg orally at bedtime for 14 nights

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Matching placebo
Study: NCT00192023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine 0.5 mg/kg/day
Description: atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atomoxetine 0.5 mg/kg/day
Description: atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine 1.2 mg/kg/day
Description: atomoxetine 1.2 mg/kg/day QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine 1.2-1.4 mg/kg/day
Description: atomoxetine 1.2 - 1.4 mg/kg/day QD, PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atomoxetine 1.2-1.4 mg/kg/day
Description: atomoxetine 1.2 - 1.4 mg/kg/day QD, PO
Study: NCT01108757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bactrim
Description: Bactrim DS BID for 3 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn starch capsules
Study: NCT04194996

Intervention type: PROCEDURE
Intervention: Surgical intervention
Description: Surgical interventions will be patient specified by treating surgeon.
Study: NCT02390427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib
Study: NCT03432793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: oral solution, single dose
Study: NCT00225225

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosiglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: dietary recommendation for weight maintenance
Study: NCT02390427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT04241744

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin 125 MG po BID
Description: prevention to develop CDI during hospitalization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin 125 MG po BID
Description: prevention to develop CDI during hospitalization
Study: NCT02419430

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBRT ClassRoom and Phone Application
Description: 2 hours/week for 6 week, in classroom intervention involving mindfulness based resilience training.focused on mindfulness and self-compassion training, including body awareness, breath awareness, mindful movement, awareness of thoughts, and awareness of emotion. Core concepts included: normalizing experience of stress and changing one's relationship with an experience; learning to be a compassionate observer of self in order to appreciate the moment; recognizing undue efforts to control something that has already happened; shifting attention to felt body sense and away from the narrative; and redirecting attention to a value as a way of evoking positive states that enhance the present moment experience. Participants also use the smartphone to track their sleep and subjective well-being.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone application only
Description: Participants will track their sleep and subjective well-being and also choose one of the following weekly challenges, which is completed via smartphone interactions:~* Joys of Life~* Count your blessings~* Think differenc, feel better~* Exercising --\> Happier~  + Exercising --\> Sleep~* Pre-Sleep routine~* Eat that frog~* Mindful Meditation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: At baseline, immediately after the last MBRT session (6 weeks) and again at 3 and 6 months, all participants will complete questionnaires, including: 1) WHO-5 Well-Being Index; 2) DASS-21; 3) VAS-Fatigue; 4) MBI-Human Services version; 5) Self-Compassion Scale; 6) Connor-Davidson 2-item resilience scale; 7) Compassion to others scale.
Study: NCT01678820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Simvastatin FDC
Description: Sitagliptin 100 mg/Simvastatin 40 mg fixed-dose combination tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to sitagliptin
Description: Matching placebo to sitagliptin 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to sitagliptin
Description: Matching placebo to sitagliptin 100 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to simvastatin
Description: Matching placebo to simvastatin 40 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to simvastatin
Description: Matching placebo to simvastatin 40 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Sitagliptin/Simvastatin FDC
Description: Matching placebo to sitagliptin 100 mg/simvastatin 40 mg FDC tablet
Study: NCT01516502

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-level laser therapy
Description: An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-level laser therapy
Description: An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: low-level laser therapy
Description: An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: low-level laser therapy
Description: An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode
Study: NCT00024102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Cyclophosphamide 100 mg/sq m PO d 1-14 + MTX 40 mg/sq m IV push d 1 \& 8 and 5-FU 600 mg/sq m IV push d 1 \& 8 q 28 days for 6 cycles OR doxorubicin 60 mg/sq m IV d 1 + cyclophosphamide 600 mg/sq m IV d 1 q 21 d for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
Study: NCT00890214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prostacyclin
Description: prostacyclin was infused as CRRT circuit anticoagulant into the arterial-line of the circuit at 4 ng/Kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
Study: NCT02894359

Intervention type: DEVICE
Intervention: cone beam imagery of cervical spine

Intervention type: DEVICE
Intervention: cone beam imagery of cervical spine
Study: NCT01678820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Sitagliptin/Simvastatin FDC
Description: Matching placebo to sitagliptin 100 mg/simvastatin 40 mg FDC tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants will continue on their stable, pre-screening metformin daily dose of \>= 1500 mg for at least 12 weeks prior to randomization and during the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants will continue on their stable, pre-screening metformin daily dose of \>= 1500 mg for at least 12 weeks prior to randomization and during the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will continue on their stable, pre-screening metformin daily dose of \>= 1500 mg for at least 12 weeks prior to randomization and during the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Following randomization, participants requiring glycemic rescue may receive open-label glimepiride initiated at a dose of 1 mg/day or 2 mg/day which may be up-titrated to 6 mg/day taken once daily with breakfast or the first main meal of the day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Following randomization, participants requiring glycemic rescue may receive open-label glimepiride initiated at a dose of 1 mg/day or 2 mg/day which may be up-titrated to 6 mg/day taken once daily with breakfast or the first main meal of the day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Following randomization, participants requiring glycemic rescue may receive open-label glimepiride initiated at a dose of 1 mg/day or 2 mg/day which may be up-titrated to 6 mg/day taken once daily with breakfast or the first main meal of the day.
Study: NCT03051022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 8 mg
Description: Dexamethasone 8 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 2 mg
Description: Morphine 2 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
Study: NCT02773680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical impedance tomography
Description: One continous electrical impedance tomography (EIT) measurement per subject of approximately 5 minutes duration (2 min prior to MDCT scanning, during end-inspiratory MDCT acquisition and 2 min after MDCT scanning)
Study: NCT01751230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WIC E-Moms
Description: Participants enrolled in the E-Moms group will receive a personalized dietary prescription to promote weight loss and arrive at pregravid weight by 6 months postpartum. Our weight loss intervention will incorporate standard WIC nutritional advice and will encouraged 150 minutes/week of moderate intensity activity, which is about 3,000 - 4,000 steps/day above baseline, as recommended for maintenance of healthy weight. Each participant will be assigned a trained weight management counselor who will provide frequent recommendations and advice and support at least once per week.
Study: NCT04199312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The MMS device will be used to perform the treatments.
Study: NCT02970513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric evaluation
Description: The purpose of this study is to determine whether the presence of pathogenic Escherichia coli in colon is associated with psychiatric disorders.
Study: NCT02314988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 3.0 grams of tranexamic acid will be poured in the surgical field and left in contact for five minutes. Subsequently, excess study solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~TXA solution will be prepared using a dose of 3 grams of tranexamic acid combined with 70 mL of sterile normal saline, for a total volume of 100 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be poured in the surgical field and left in contact for five minutes. Subsequently, excess solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~The placebo solution will be 100 mL of sterile normal saline.
Study: NCT02086162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based motivational decision support system

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCI Education
Study: NCT01737996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 + faldaprevir
Description: fixed dose combination
Study: NCT01463592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RENESSANS , INTERFERON ALPHA 2b, Ribavirin
Description: ORAL RENESSANS 5gm. Twice Daily +INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Alfa-2b AND RIBAVIRIN
Description: INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RENESSANS
Description: ORAL RENESSANS 5gm. Thrice Daily{active iodine 300mg} for 6months
Study: NCT00792688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYC-101 Gel (0.1%)
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYC-101 Gel (0.1%)
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYC-101 Gel (1.0%)
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYC-101 Gel (1.0%)
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYC-101 Placebo
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYC-101 Placebo
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Study: NCT02225366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LL37
Description: Starting dose 250 µg/tumor. The injections will be given every 7 days for up to 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photographs
Description: Tumors measured and photographed one week before receiving LL37, and again at 4 weeks after LL37. Then photographs of the LL37 injected sites taken at 8 weeks.
Study: NCT02042326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: For patients with swallowing problems, and for children under 6 years and / or who have an inability to swallow tablets, the 1mg/ml solution form should be used.
Study: NCT01106677

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin immediate release
Description: The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin immediate release
Description: The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin immediate release
Description: The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin immediate release
Description: The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.